Persistent Use of Secondary Preventive Drugs Declines Rapidly During the First 2 Years After Stroke

被引:306
作者
Glader, Eva-Lotta [1 ]
Sjolander, Maria [2 ]
Eriksson, Marie [1 ]
Lundberg, Michael [3 ]
机构
[1] Umea Univ Hosp, Dept Publ Hlth & Clin Med, S-90185 Umea, Sweden
[2] Umea Univ Hosp, Dept Pharmacol & Clin Neurosci, S-90185 Umea, Sweden
[3] Natl Board Hlth & Welf, Stockholm, Sweden
关键词
medication persistence; secondary prevention; stroke; ISCHEMIC-STROKE; ADHERENCE;
D O I
10.1161/STROKEAHA.109.566950
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-To prevent new cardiovascular events after stroke, prescribed preventive drugs should be used continuously. This study measures persistent use of preventive drugs after stroke and identifies factors associated with persistence. Methods-A 1-year cohort (21 077 survivors) from Riks-Stroke, the Swedish Stroke Register, was linked to the Swedish Prescribed Drug Register. Results-The proportion of patients who were persistent users of drugs prescribed at discharge from hospital declined progressively over the first 2 years to reach 74.2% for antihypertensive drugs, 56.1% for statins, 63.7% for antiplatelet drugs, and 45.0% for warfarin. For most drugs, advanced age, comorbidity, good self-perceived health, absence of low mood, acute treatment in a stroke unit, and institutional living at follow-up were independently associated with persistent medication use. Conclusion-Persistent secondary prevention treatment declines rapidly during the first 2 years after stroke, particularly for statins and warfarin. Effective interventions to improve persistent secondary prevention after stroke need to be developed. (Stroke. 2010; 41: 397-401.)
引用
收藏
页码:397 / 401
页数:5
相关论文
共 7 条
[1]   Non-adherence to aspirin or oral anticoagulants in secondary prevention after ischaemic stroke [J].
De Schryver, ELLM ;
van Gijn, J ;
Kappelle, LJ ;
Koudstaal, PJ ;
Algra, A .
JOURNAL OF NEUROLOGY, 2005, 252 (11) :1316-1321
[2]   Attrition and non-compliance in secondary stroke prevention trials [J].
Gencheva, E ;
Sloan, M ;
Leurgans, S ;
Raman, R ;
Harris, Y ;
Gorelick, P .
NEUROEPIDEMIOLOGY, 2004, 23 (1-2) :61-66
[3]   Adherence to secondary stroke prevention strategies - Results from the German stroke data bank [J].
Hamann, GF ;
Weimar, C ;
Glahn, J ;
Busse, O ;
Diener, HC .
CEREBROVASCULAR DISEASES, 2003, 15 (04) :282-288
[4]   In-hospital initiation of secondary stroke prevention therapies yields high rates of adherence at follow-up [J].
Ovbiagele, B ;
Saver, JL ;
Fredieu, A ;
Suzuki, S ;
Selco, S ;
Rajajee, V ;
McNair, N ;
Razinia, T ;
Kidwell, CS .
STROKE, 2004, 35 (12) :2879-2883
[5]   Compliance with secondary prevention of ischemic stroke - A prospective evaluation [J].
Sappok, T ;
Faulstich, A ;
Stuckert, E ;
Kruck, H ;
Marx, P ;
Koennecke, HC .
STROKE, 2001, 32 (08) :1884-1889
[6]   A survey on adherence to secondary ischemic stroke prevention [J].
Wang, YJ ;
Wu, D ;
Wang, YL ;
Ma, RH ;
Wang, CX ;
Zhao, WK .
NEUROLOGICAL RESEARCH, 2006, 28 (01) :16-20
[7]   Secondary prevention in a large stroke population - A study of patients' purchase of recommended drugs [J].
Wettermark, Bjoern ;
Persson, Anna ;
von Euler, Mia .
STROKE, 2008, 39 (10) :2880-2885